The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor.
10.4093/jkd.2014.15.3.158
- Author:
Won Jin KIM
1
;
Sang Soo KIM
Author Information
1. Department of Internal Medicine, Pusan National University Hospital, Busan, Korea. drsskim7@gmail.com
- Publication Type:Original Article
- Keywords:
Type 2 diabetes mellitus;
Sodium glucose cotransporter 2;
Safety
- MeSH:
Diabetes Mellitus, Type 2;
Glucose*;
Humans;
Hypoglycemia;
Insulin;
Reproductive Tract Infections;
Sodium*;
Urinary Tract Infections
- From:Journal of Korean Diabetes
2014;15(3):158-162
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Anti-diabetic drugs for effectively lowering glucose with limited side effects are necessary in providing patient-centered diabetic management. Sodium glucose cotransporter 2 (SGLT 2) inhibitors provide a novel therapeutic approach for managing type 2 diabetic patients by lowering glucose levels by increasing urinary excretion of glucose independently of insulin secretion or action. Several SGLT 2 inhibitors were recently approved and available in the US, European and Korean markets. SGLT 2 improved glycemic control with low propensity of hypoglycemia. Through the clinical trials, most SLGT2 inhibitors were generally well tolerated. Genital tract infections were more frequent in most clinical studies of SGLT2 inhibitors and urinary tract infections were slightly increased in some studies. This review will describe the main safety issues that have been uncovered in clinical trials of SGLT 2 inhibitors.
